<DOC>
	<DOCNO>NCT01374789</DOCNO>
	<brief_summary>The primary objective study assess efficacy combination consist gemcitabine/cisplatin panitumumab patient urothelial carcinoma wild-type HRAS ( non-mutated status ) . The progression-free survival rate 12 month compare expectation derive historical data , verify randomise control group without antibody .</brief_summary>
	<brief_title>PURO Panitumumab Combination With Gemcitabine/Cisplatin Advanced Urothelial Cancer</brief_title>
	<detailed_description>Mutation ras oncogene frequently observe human tumour occur approximately 30 % cancer type . Frequent mutation `` hot spot '' occur codon 12 ( glycine valine ) , codon 13 ( glycine cysteine ) codon 61 ( glutamine arginine , lysine leucine ) ( Bonner et al . 1993 , Levesque et al . 1993 ) . Point mutation ras gene result blockade intrinsic GTPase activity , physiological mechanism switch ras GTPases . The consequence persistent up-regulation signal pathway increase cell proliferation . The first HRAS mutation association bladder cancer describe establishment human urinary bladder carcinoma cell line T24 . In study , research group lead Fitzgerald able demonstrate HRAS gene mutation present urine sediment 44 % patient urinary bladder cancer ( Fitzgerald et al . 1995 ) . Viola et al . subsequently investigated whether increased mutation rate accompany increase expression ra proteins bladder cancer . It show indeed increased expression ra protein dedifferentiate tumour carcinoma situ , whereas highly differentiated tumour exhibit rate expression ( Viola et al . 1985 ) . At present , clinical evidence , finding obvious lack activity EGFR antibodies colorectal cancer RAS-related mutation , likewise valid urothelial carcinoma . However , aim study detect first signal activity type cancer , chance miss evidence phase II trial limit patient number high anyway , seem sensible , miss opportunity `` enrichment '' . In case clearly positive signal efficacy present trial , subsequent phase II study may focus HRAS mutate tumor . Overexpression EGF receptor bladder cancer describe many research group ( Colquhuon &amp; Mellon , 2002 ) associate advanced stage tumour , progression tumour poor clinical prognosis . The EGFR antibody cetuximab ( Erbitux® ) investigate human urothelial carcinoma cell line mouse model human bladder carcinoma . Cetuximab find inhibit tumorigenesis metastatic progression vivo vitro mean suppression angiogenesis simultaneous induction apoptosis ( Perotte et al. , 1999 ; Inoue et al. , 2000 ) . Similar result also report urothelial carcinoma tyrosine kinase inhibitor gefitinib ( Villares et al. , 2007 , Shrader et al. , 2007 ) . There currently two on-going study cetuximab metastatic bladder cancer : randomise phase II study first-line treatment Gemcitabine Cisplatin +/- Erbitux ( NCT00645593 ) randomise phase II study second-line treatment Erbitux +/- Paclitaxel ( NCT00350025 ) . The HRAS mutation rate urothelial carcinoma approximately 40 % . The primary objective study assess efficacy combination consist gemcitabine/cisplatin panitumumab patient wild-type HRAS ( non-mutated status ) . The progression-free survival rate 12 month compare expectation derive historical data , verify randomise control group without antibody .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable urothelial carcinoma bladder upper urinary tract Wildtype HRAS Male female subject &gt; 18 year age General condition ECOG 01 Life expectancy least 12 week Women childbearing potential : negative pregnancy test use effective contraception ( oral contraceptive , coil ) ; men : use adequate male contraception ( condom ) 3 month discontinuation panitumumab therapy Locally advance metastatic disease ( T3b , T4 and/or N+ and/or M+ ) At least one unidimensionally measurable lesion detectable CT MRI correspond RECIST criterion Adequate haematological , hepatic , renal metabolic function parameter : Leukocytes &gt; 3000/mm³ , ANC ≥ 1500/mm³ , platelet ≥ 100,000/mm³ , hemoglobin &gt; 9 g/dl Creatinine clearance ≥ 50 ml/min serum creatinine ≤ 1.5 x upper limit normal Bilirubin ≤ 1.5 x upper limit normal , GOTGPT ≤ 2.5 x upper limit normal absence liver metastasis , ≤ 5 x upper limit normal presence liver metastasis , AP ≤ 5 x upper limit normal Magnesium ≥ low limit normal ; calcium ≥ low limit normal INR PTT &lt; 1.5 x upper limit normal reference range HRAS mutation Absence abovelisted inclusion criterion Dialysisdependence follow nephrectomy Patients cerebral tumour and/or cerebral metastasis Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrolment . Patients uncontrolled hypertension ; systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical treatment History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Patients thrombotic embolic event , stroke pulmonary embolism Patients recent know history haemorrhagic diathesis Known significant neurological psychiatric disorder , include dementia epileptic seizure Serious inflammatory eye condition , hear impairment Pulmonary ( pO2 &lt; 60 mmHg ) , haemopoietic ( e.g . serious bone marrow aplasia ) , hepatic renal disorder Patients poorly control diabetes mellitus Serious bacterial fungal infection ( &gt; grade 2 NCI CTC Version 3 ) Chronic hepatitis B C ; HIV infection Autoimmune disease Allergic reaction one medication use Status post organ transplantation Status post autologous bone marrow transplantation stem cell transplantation 4 month prior study commencement Manifest secondary malignancy form cancer previous 5 year ( exclude basalioma , situ cervical cancer , incidental prostatic cancer ) Subject pregnant breast feeding , plan become pregnant within 6 month end treatment Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 3 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) . Active participation clinical study previous 4 week Prior systemic therapy cytostatics immunotherapeutic agent Concurrent use anticancer treatment study commencement Intravesical chemotherapy previous 4 week Radiotherapy previous 4 week Previous radiotherapy lesion use evaluation tumour response irradiate Patients close institution accord authority court decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>